NEW YORK (GenomeWeb News) – GeneNews and Shanghai Biochip today announced a deal to establish the first Sentinel Centre for Personalized Medicine.
The partners are creating the center, which will be based in Shanghai, in order to co-develop and commercialize products based on GeneNews' gene expression technology called the Sentinel Principle. They inked a memorandum of understanding in February to establish the center.
As part of the deal, SBC has non-exclusive rights to market and sell GeneNews' ColonSentry test, which is based on the Sentinel Platform technology, in China. Further details of the agreement were not disclosed.
"The signing of this agreement represents a significant milestone for the commercialization of our Sentinel Principle platform, opens the door to the Chinese market, and provides us with access to Shanghai Biochip's significant expertise in gene expression profiling platforms and to its well-established clinical network," Gailina Liew, president and COO of Toronto-based GeneNews, said in a statement.
The company develops molecular diagnostics using blood-based RNA molecular signatures. In June it raised $2.6 million in a rights offering.
SBC is a national engineering center for advanced microarray and gene expression profiling technologies in China. It specializes in genetics, protein, and other microorganism detection.